Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose.

ABSTRACT:

Background

Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This post hoc analysis assesses the impact of OCS dose at baseline (≤10 or >10 mg·day^-1) on long-term outcomes of dupilumab treatment.

Methods

Annualised severe asthma exacerbation rates, forced expiratory volume in 1 s (FEV₁), measures of asthma control and quality of life, and OCS dose were evaluated in patients from the phase 3 VENTURE trial with severe OCS-dependent asthma, further categorised by OCS dose ≤10 or >10 mg·day^-1 at parent study baseline (PSBL), who enrolled in TRAVERSE.

Results

Dupilumab reduced the annualised exacerbation rate in VENTURE, and it r

SUBMITTER: Domingo C 

PROVIDER: S-EPMC10645323 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature